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Thrombolytic Compound 

Comparison 

Robert S. Kidd 
Introduction 
The topic of heart attacks and their treatment may not seem like a 
very interesting topic, but it is the number one killer in the adult population 
of the United States. Carey writes that "coronary heart disease 'remains 
America's number one killer, responsible for about 768,00 deaths each 
year--or about a third of all deaths,' he [Dr. Windom, assistant secretary 
for health] said. 'At some point in their lives,' Dr. Windom added, 'one out 
of every four or five people will feel the pain and constriction of a heart 
attack--pressure or pain in their chest or pain in their left arm.' When it 
happens, he advised, 'Don't waste time hoping against hope that the pain 
will go away... get help quickly (1, p. 23)." Thrombolytic compounds were 
first used for myocardial infarction in 1959. The problem today is that not 
enough people receive thrombolytic therapy for various reasons. Victims 
usually do not get to the hospital soon enough, or do not meet certain 
criteria that is required to receive thrombolytic therapy. Through public 
awareness programs and physician screening more people may receive 
this therapy in the future. 
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Biological Background 
The need for thrombolytic drugs anse from an occlusion in the 
coronary arteries. Occlusions cause localized anemia by preventing the 
flow of blood enriched with oxygen to the muscles of the heart. If the heart 
is not supplied with blood, it cannot pump blood enriched with oxygen to the 
rest of the body. Ischemia leads to chest pains, pressure in the chest, and 
onset of myocardial infarction. Death is also possible if the occlusion is not 
reperfused or if the other vessels cannot sufficiently increase the delivery of 
oxygen to the anemic tissue. 
PULMONARY 
ARTERY 
LEFT 
CORONARY 
ARTERY 
A clot can block 
the flow of blood 
to an entire 
section of the 
heart. (2, p. 717) 
An occlusion in a coronary artery can be a clot formed locally, a 
thrombus, or it can be a foreign clot that travelled through the circulatory 
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system and lodged in the coronary artery, an embolus. Artheriosclerosis, 
the reduction of the blood flow due to deposits on the walls of the arteries, 
can lead to a thrombus, the most common occlusion. 
Artheriosclerosis begins by the damaging of the epithelial lining of a 
coronary artery. The damage causes the accumulation of lipids, smooth 
muscle cells, calcium and other debris around the damaged area. This 
accumulation is called a plaque deposit. The deposit is soon capped by blood 
platelets. Wessels and Hopson state that "This problem is very serious 
because plaque accumulates preferentially in the arteries of the heart and 
the neck (3, p. 746)." 
Blood Lipids (Cholesterol) Fibrous Cap 
(a) Endothelial Cells (b) Platelets (c) Fatty Core 
An example of how a 
vessel can narrow. 
(3, p. 746) 
The net effect is the narrowing and hardening of the entire artery, and the 
roughening of the interior surface of the artery. The rough area can be 
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sensed by the clotting factors in the blood which begins a cascade of 
enzymatic activations that eventually form an array of fibrin molecules. 
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The second to the last step of the cascade is the most important one. The 
zymogen, fibrinogen, consists of two globular regions connected by triple-
stranded alpha-helical rod regions. The globular regions contain two sets 
of highly negatively charged fibrinopeptides A and B. Thrombin catalyzes 
the cleaving of four arginine-glycine peptide bonds that link the 
fibrinopeptides to the center globular region to form a fibrin monomer. The 
net effect is the increase of the net charge of the center globular region 
from -8 to +5. Spontaneous ordering into fibrous arrays occurs because the 
change promotes electrostatic interactions between the center globular 
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region and the negatively charged terminal units. The newly formed fibrin 
has a porous character that can be seen in the diagram below and is very 
important in the action of thrombolytic compounds. 
Fibrinogen 
ThromDln l,- FibrinODeDUdes ~ 7 AI .nd 8 
230 A 
123 nmJ Reaction of fibrin 
Fibrin formation. (4, p. 249) 
The fibrin molecules attach to one another and begin to catch red blood cells 
and platelets in their fiberous web. 
A red blood cell 
caught in a fiberous 
web. (2, p. 707) 
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When platelets are caught and break open, they release their internal 
agents. Thromboxane A2, a prostaglandin, is one of these agents that 
promotes platelet aggregation and vascular constriction. The formation of 
these insoluble networks constricts the vessel and stops the flo\v of 
oxygenated blood through the vessel. The thrombus is the cause of the onset 
of a cardiac arrest. The sooner the thrombus can be reperfused the better 
the chances are to save the tissue fed by the blocked artery and to save the 
victim's life. The problem is that most people do not receive thrombolytic 
therapy soon enough. 
These newly formed clots are open to lysis by plasmin, a serine protease. 
Plasmin is the active form of the zymogen, plasminogen. Plasminogen 
activator converts inactive plasminogen to the active enzyme, plasmin: 
plasminogen activator 

plasminogen -----------_~plasmin 

The porous character of fibrin allows the plasmin molecules to access the 
interior of the fiber structure. The hydrolyzing of the peptide bonds occurs 
in the rod regions. If fibrin did not have a porous character, the plasmin 
molecules would not be able to diffuse into the fibers and dissolve the clot. 
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The catalytic triad of plasmin carries out this hydrolysis by a mechanism 
common to all serine proteases. Aspartate, histidine, and serine make up 
the catalytic triad in plasmin and are helped by an oxyanion hole in 
transition state stabilization. 
Now that the mechanism of clot formation and hydrolysis by plasmin 
has been explained, the focus can tum to how the activity of plasmin can be 
enhanced or activated artificially. As noted plasminogen activator activates 
the clot lysing protease. The three compounds to be discussed are activase, 
streptokinase, and eminase. All three of these thrombolytic compounds 
attempt to increase the concentration of plasminogen activator. However, 
the way the increase is brought about is different. Initially all three 
compounds have to produce enough active plasmin to overcome inhibitors 
that naturally circulate in the blood. Alpha-antiplasmin and alpha2­
macroglobulin are depleted rapidly in all cases with therapeutic doses. 
Activase 
Activase, developed, patented and produced by Genentech, was cleared 
for marketing by the United States Food and Drug Administration in 
November of 1987. The Food and Drug Administration also approved 
Genentech's claim that activase saves lives in February of 1989. Sales of 
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activase totaled $151.4 million in 1988 and increased thirty percent to $196.4 
million in 1989 (5, p. 947M). Activase, the only biosynthetic thrombolytic 
compound produced by recombinant DNA technology, costs $2332 for a 
single treatment (6, p. 2). Genentech invested $220 million in researching 
and developing activase and must reclaim their investment through its 
high prices. Sales of activase accounted for over fifty percent of 
Genentech's total sales in 1989. This high percentage makes Genentech 
very protective over the market it has gained for the product. An example of 
their protectiveness occurred in midsummer of 1989. Genentech, a San 
Francisco based company, asked two California senators to write the Food 
and Drug Administration and request that a special advisory committee be 
formed to review eminase, the most recently developed compound. Two 
weeks later, SmithKline Beecham, developer of eminase, was notified that 
it would have to appear before the committee on October 31, 1989. This move 
by Genentech proved to postpone eminase's approval until November of 1989 
and postpone distribution in the United States until January 1, 1990. 
The structure of activase is very similar to that of naturally occurring 
plasminogen activator. The active 527 amino acid sequence is identical, but 
slight variations occur in the carbohydrate side chains. Intravenous 
activase is applied over a period of approximately four hours through an 
intravenous infusion. It works by increasing the levels of plasminogen 
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activator by approximately one thousand times. This increase in turn 
activates more plasmin to lyse the clot. One of the heralded traits of 
activase is its clot specificity. Activase is supposed to preferentially bind to 
fibrin in clots, and not to affect circulating fibrinogen. Hussar states that 
"It [activase] binds to fibrin in a thrombus and converts the trapped 
plasminogen to plasmin, but it has comparative little effect on free 
circulating plasminogen (7, p. 41)." However, Boyle states that "In 
practice, some reduction in circulating fibrinogen does occur (8, p. 84)." 
The small effect of activase on circulating fibrinogen seems to be an 
advantage of activase, but it could be a disadvantage of activase. McEvoy 
states that "Reocclusion of the infarct-related coronary artery following 
therapy with rt-PA [activase] generally has occurred in approximately 10­
20% of patients, although higher reocclusion rates (up to 45%) have been 
reported (9, p. 729)." Activase's relatively small effect on circulating 
fibrinogen could be the cause of this problem. The other two compounds 
(especially streptokinase) lack activase's specificity and break down more of 
the circulating fibrinogen. 
Another problem associated with activase is its short half-life. Its 
half-life is only five minutes compared to eminase's half-life of 
approximately ninety minutes. McEvoy states that "More than 50% of t-PA 
is cleared from plasma within 5 minutes after discontinuance of IV 
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infusion of altepase [activase], and approximately 80% is cleared within 10 
minutes (9, p. 728)." The use of an anticoagulant with activase is required 
to prevent reocculsion. Heparin is a natural anticoagulant that is available 
for use with activase. Abram states that "Heparin acts in conjunction with 
antithrombin III to inactivate several clotting factors (IX, X, XXI and 
perhaps XII) and thrombin so that thrombus formation is prevented (10, p. 
535)." Disadvantages of heparin are similar to those of activase. It has a 
relatively short half-life, so continuous IV infusion is required and it is 
obtained at a fairly high cost. Weiss records that "t-PA [activase] must be 
given simultaneously with the anticoagulant heparin, increasing the risk 
of bleeding. The bottom line, said Sherry, is that t-PA now proves to have 
comparable bleeding to streptokinase (11, p. 22)." The following picture 
shows how a coronary vessel's flow is actual restored after activase is 
administered. 
Picture of reperfusion 
with activase. (12, p. 611) 
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One distinct advantage that activase has over its two competitors is that it 
IS not antigenic. Activase treatment can be given repeatedly without 
problems of antibody build up against it. After repeated treatments, the 
body will build a resistance to antigenic streptokinase and eminase. 
Subsequent treatment of these two compounds will be less effective and 
possibly produce allergic reactions. 
Streptokinase 
Streptokinase has reportedly been used used to treat myocardial 
infarction since 1959. Since its patent has long expired, several companies 
market the compound under different names. Hoechst-Roussel markets it 
as streptokinase, and other smaller companies market it under the names 
Kabikinase and Streptase. A single treatment of the nonenzymatic protein, 
streptokinase, costs only $186.48. Streptokinase is derived from streptococci 
bacteria from which it got its name. Intracoronary or intravenous 
streptokinase therapy is available. Intravenous therapy is more common 
because of limited facilities for intracoronary therapy and other difficulties 
that arise from its use. Once treatment is initiated, instead of artificially 
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increasing plasminogen activator level, McEvoy states that "Streptokinase 
acts in a complex manner with plasminogen or plasmin to produce an 
activator complex that converts residual plasminogen into the proteolytic 
enzyme plasmin (9, p. 733)." In addition to increasing the conversion of 
plasminogen to plasmin, streptokinase also decreases plasma and blood 
viscosity, decreases erythrocyte aggregation, decreases blood pressure, 
decreases vascular resistance and possibly alters platelet function. These 
additional functions of streptokinase may help to prevent the reocclusion of 
reperfused arteries. 
Streptokinase is most effective on recently formed clots, so the sooner the 
treatment is started the better survival rates. If applied later than 
recommended the treatment can still be beneficial, but not as beneficial as 
when applied early. When thrombolytic treatment was initiated within 
four hours of onset of pain, 6.4% of the victims died from vascular causes 
within thirty-five days and 9.2% died in the same time period if the 
treatment was initiated from five to twenty-four hours after onset of pain as 
shown by ISIS-2 (13, p. 352). This $tudy shows an approximately thirty 
percent reduction in vascular death if the treatment was initiated early. 
In contrast to activase and heparin, streptokinase is usually 
supplemented with aspirin. Aspirin is an effective antiplatelet which 
prevents platelet aggregation. It prevents the synthesis of thromboxane A2 
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in platelets. Thromboxane A2 stimulates the aggregation of platelets and 
promotes vascular constriction. The effects of aspirin act for the entire ten 
day life span of the platelets. Dosages for antiplatelet effects are 150-325 
milligrams daily and adverse effects are uncommon. Aspirin used alone 
after the onset of cardiac arrest significantly reduces vascular mortality as 
shown by 1818-2 (13, p. 349). When the two compounds are used together, 
there is a marked decrease of vascular mortality over either one used alone. 
1818-2 states that "Their [streptokinase and aspirin] separate effects on 
vascular deaths appeared to be additive: 343/4292 (8.0%) among patients 
allocated both active agents vs 568/4300 (13.2%) among those allocated 
neither (odds reduction: 42% SD 5; 95% confidence limits 34-50%) (13, p. 
349)." 
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A problem associated with streptokinase is that its antigenic. The body 
will produce antibodies against the protein if it is used repeatedly. This 
response should decrease streptokinase's effectiveness and possibly cause 
allergic reactions. 
Emjnase 
Eminase, the newest competitor in the thrombolytic market, is being 
distributed by a joint effort of SmithKline Beecham and U pjohn. It is the 
culmination of fifteen years of research and development at a cost of $190 
million. Eminase is a modified, second generation form of streptokinase. 
It is also known by the acronym, APSAC, which stands for Anisoylated 
Plasminogen Streptokinase Activator .Qomplex. As the name implies, it is 
a complex. This complex is composed of acylated, inactive streptokinase 
combined with human lys-plasminogen. Human lys-plasminogen, 
truncated human plasma, is supposed to preferentially bind to fibrin in 
clots and not to circulating fibrinogen. The acyl group is hydrolyzed slowly 
to produce a time release of the active compound that converts the 
plasminogen into plasmin. 
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Eminase has a few distinct advantages that were obvious even before 
clinical trials began. Perrin records one distinct advantage eminase has is 
that '''Eminase is administered over a two- to five-minute period with a 
simple syringe,' said Anderson. 'Other thrombolytic agents such as 
streptokinase or tissue plasminogen activator [activase] take a one to three 
hours or more to administer and require an intravenous line as well as a 
monitoring pump' (14, p. 20)." If it proves to be as an effective life saver as 
the other compounds, many experts see this single advantage as one that 
could win overwhelming support of eminase. Sun writes that "Jeffery 
Anderson of the University of Utah, who was an investigator in the APSAC 
study, points out that a heart attack victim has many clinical 
complications. 'With APSAC, you don't have to worry about an i.v. drip. 
You just give it in 2 minutes and then you can deal with the other things,' 
Anderson says (15, p. 1268)." 
Another distinct advantage eminase has over the other two compounds 
(especially activase) is its half-life. Eminase has a half-life of about ninety 
minutes which is attributed to the acyl group's slow hydrolysis which 
releases the active compound. Activase has a half-life of only five minutes 
which causes many problems with reocclusion. Streptokinase's half-life is 
twenty three minutes. The long half-life of eminase prevents the need for 
potentially hazardous anticoagulants. One of the primary objections to 
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eminase's quick administration is that if bleeding occurs the drug infusion 
can not be stopped. If bleeding occurs with streptokinase or activase the 
administration of the drug can simply be stopped. However, there is a 
antidote for streptokinase that should work for eminase since it is only a 
streptokinase complex. Aminocaproic acid is the antidote for streptokinase 
and it can be given orally or intravenously. 
Since the market for thrombolytic therapy has been estimated to be up to 
a billion dollar a year industry in the near future, all the companies are 
trying to get mass approval of their product. Perrin states that "SmithKline 
Beecham and Upjohn have begun a program to both inform physicians of 
the benefits of thrombolytic therapy and help educate the general public 
about heart attack symptoms and the importance of seeking prompt 
medical attention (14, p. 20)." The possible victims could take daily doses of 
aspirin, which is currently recommended by doctors. The education of 
these people to the early symptoms of heart attack could decrease the time 
before a thrombolytic compound can be administered. The use of eminase 
would allow the injection of a thrombolytic compound at home, or in an 
ambulance on the way to a hospital. As studies have shown, the sooner the 
thrombolytic compound is administered the sooner the occlusion can be 
reperfused, and the less chance of permanent damage to the heart tissue. 
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Analysis 
The results of all the studies show that thrombolytic therapy does 
save lives no matter which compound is used. Sun writes that "Not since 
the 1960s, when coronary care units were introduced has a single 
technology improved a heart attack victim's chances of survival so 
dramatically as thrombolytics, according to Braunwaly and other experts 
(15, p. 1267)." Thrombolytic therapy does have it drawbacks. McEvoy states 
that "Plasmin is a relatively nonspecific serine protease that is capable of 
degrading fibrin, fibrinogen, and other precoagulant proteins such as 
factors V, VIII, and XII (9, p. 726)." Increased plasmin concentration will 
then not only lyse clots in coronary arteries, but also prevent clots from 
being formed until new precoagulation proteins can be made. The 
consequences include the prevention of immediate surgery on the patient 
and any other type of therapy that would break the skin. The plasmin will 
also lyse clots elsewhere in the body that are considered to be beneficial. 
Side effects are mostly associated with bleeding complications, but 
vomiting, fever, and hypotension have also been reported. The most serious 
side effect is a stroke. Marx states that "The incidence of stroke is 
sufficiently low--from about 0.5% to 1.0% of the patients who receive 
thrombolytic agents have the problem--compared to the life-saving benefits 
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of the therapy to justify its use (16, p. 1506). II All the side effects combined 
were rare and occurred in less than three percent of all patients in all the 
studies. Another problem with thrombolytic therapy is its high cost 
especially with activase and eminase. Medicare does not cover the high 
expense of the compounds separately, it is just included in the limited 
coverage of the overall treatment for a heart attack. Activase and eminase 
may decrease the amount of time the victims need to stay in the hospital, 
but at only $186.48 streptokinase may prove to reduce the stay equally well 
(6, p.2). However, if one compound is found to be better than the other 
compounds can one put a limit on the price of a treatment that can save a 
human life. 
Although thrombolytic therapy does have problems with side effects, the 
benefits far outweigh the disadvantages. The AIMS trial study done on 1004 
patients showed a forty-seven percent mortality reduction in those treated 
with eminase versus those victims given placebo (17, p. 545). The advisory 
committee decided to discontinue use of placebo because of the great 
decrease in mortality with the use of a thrombolytic compound. 
Thrombolytic compounds are also known as fibrinolytic compounds 
because of their general ability to lyse fibrin clots. For this reason, 
thrombolytic technology can be applied to a number of other clot related 
problems. Any clot that has formed that is not medically desirably can be 
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lysed in a similar procedure as used to lyse coronary clots. Examples 
include: subclavian vein occlusion, femoropopliteal artery occlusion, 
basilar artery occlusion, cerebral infarction, deep vein thrombosis, and 
pulmonary embolism. Future thrombolytic drugs may be linked to 
monoclonal antibodies that will truly direct the drug to a specific clot. 
The ultimate question is not which compound dissolves clots the best or 
which one has the least number of side effects, but it is which compound 
has the best survival rate. All the studies previously done have used 
different techniques and compounds to supplement the particular 
thrombolytic that is being tested. For example, some patients receive 
aspirin, heparin, angioplasty, beta-blockers, etc. A single large scale study 
with direct comparisons between the different compounds is needed for a 
definitive winner. Eventually, I believe the answer will be which compound 
works best when supplemented with other compounds and treatments. For 
example, a study using eminase and aspirin should show that their effects 
are also additive. 
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